These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
587 related articles for article (PubMed ID: 30660511)
61. Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial. Harrington KJ; Ferris RL; Gillison M; Tahara M; Argiris A; Fayette J; Schenker M; Bratland Å; Walker JWT; Grell P; Even C; Chung CH; Redman R; Coutte A; Salas S; Grant C; de Azevedo S; Soulières D; Hansen AR; Wei L; Khan TA; Miller-Moslin K; Roberts M; Haddad R JAMA Oncol; 2023 Jun; 9(6):779-789. PubMed ID: 37022706 [TBL] [Abstract][Full Text] [Related]
62. Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. Klein O; Kee D; Nagrial A; Markman B; Underhill C; Michael M; Jackett L; Lum C; Behren A; Palmer J; Tebbutt NC; Carlino MS; Cebon J JAMA Oncol; 2020 Sep; 6(9):1405-1409. PubMed ID: 32729929 [TBL] [Abstract][Full Text] [Related]
63. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. Haakensen VD; Nowak AK; Ellingsen EB; Farooqi SJ; Bjaanæs MM; Horndalsveen H; Mcculloch T; Grundberg O; Cedres SM; Helland Å J Transl Med; 2021 May; 19(1):232. PubMed ID: 34059094 [TBL] [Abstract][Full Text] [Related]
64. First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial. Cytryn SL; Moy RH; Cowzer D; Shah RH; Chou JF; Joshi SS; Ku GY; Maron SB; Desai A; Yang J; Sugarman R; Rao D; Goldberg Z; Charalambous C; Lapshina M; Antoine A; Socolow F; Trivedi N; Capanu M; Gerdes H; Schattner MA; Simmons M; Lacouture ME; Paroder V; Tang LH; Shia J; Ilson DH; Solit DB; Berger MF; Janjigian YY Lancet Oncol; 2023 Oct; 24(10):1073-1082. PubMed ID: 37666264 [TBL] [Abstract][Full Text] [Related]
65. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151 [TBL] [Abstract][Full Text] [Related]
66. Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma. Takeda M; Ohe Y; Horinouchi H; Hida T; Shimizu J; Seto T; Nosaki K; Kishimoto T; Miyashita I; Yamada M; Kaneko Y; Morimoto C; Nakagawa K Lung Cancer; 2019 Nov; 137():64-70. PubMed ID: 31557561 [TBL] [Abstract][Full Text] [Related]
67. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab? Disselhorst MJ; Lubeck Y; van der Noort V; Quispel-Janssen J; Seignette IM; Sanders J; Peters D; Hooijberg E; Baas P Lung Cancer; 2022 Nov; 173():49-52. PubMed ID: 36122471 [TBL] [Abstract][Full Text] [Related]
68. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. Fennell DA; King A; Mohammed S; Greystoke A; Anthony S; Poile C; Nusrat N; Scotland M; Bhundia V; Branson A; Brookes C; Darlison L; Dawson AG; Gaba A; Hutka M; Morgan B; Bajaj A; Richards C; Wells-Jordan P; Thomas A; Lancet Oncol; 2022 Mar; 23(3):374-381. PubMed ID: 35157829 [TBL] [Abstract][Full Text] [Related]
69. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604 [TBL] [Abstract][Full Text] [Related]
70. JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma. Miyamoto Y; Kozuki T; Aoe K; Wada S; Harada D; Yoshida M; Sakurai J; Hotta K; Fujimoto N J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34711664 [TBL] [Abstract][Full Text] [Related]
71. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526 [TBL] [Abstract][Full Text] [Related]
72. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study. Zauderer MG; Szlosarek PW; Le Moulec S; Popat S; Taylor P; Planchard D; Scherpereel A; Koczywas M; Forster M; Cameron RB; Peikert T; Argon EK; Michaud NR; Szanto A; Yang J; Chen Y; Kansra V; Agarwal S; Fennell DA Lancet Oncol; 2022 Jun; 23(6):758-767. PubMed ID: 35588752 [TBL] [Abstract][Full Text] [Related]